Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial.

Louise A A GerbensS A S HamannM W D BrouwerE RoekevischM M G LeeflangPhyllis I Spuls

Published in: The British journal of dermatology (2018)

Based on this relatively small pragmatic study, MTX and AZA seem to be effective and safe as maintenance treatments in moderate-to-severe AD up to 5 years. Few patients in both groups survive on their originally allocated drug although some discontinued because of controlled AD.

Keyphrases

atopic dermatitis
end stage renal disease
ejection fraction
newly diagnosed
early onset
prognostic factors
drug induced
high dose
randomized controlled trial
emergency department
high intensity
patient reported outcomes
clinical trial